Skip to main content

Advertisement

ADVERTISEMENT

News

Celularity

https://celularity.com/celularity-expands-advanced-biomaterial-product-commercial-portfolio-with-acquisition-of-rebound-product-from-sequence-lifescience-inc/

Celularity expands its current biomaterial portfolio with the acquisition of Rebound, a full-thickness placental-derived allograft matrix, from Sequence LifeScience. The company expects Rebound sales to contribute revenue in Q424 and fulfill expected FY24 biomaterial sales.

Advertisement

Advertisement

Advertisement